Takeda Pharmaceutical Company Limited
TKPHFOTCHealthcare● Active
$32.60
+$2.13(+6.99%)
Market Cap$51.5B
P/E Ratio—
52W High$39.2
52W Low$26.33
Takeda Pharmaceutical Company Limited (TKPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TKPHF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.10
Est. -$0.15 · +35.2%
Revenue
$6.89B
Est. $7.07B · -2.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 6-Quarter EPS Beat Streak
TKPHF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.38 | — | — | — | $7.32B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.15 | -$0.10 | +35.2% | $6.89B | $7.07B | -2.5% |
| ▲ Q1 FY2026 | Jan 29, 2026 | $0.28 | $0.42 | +52.4% | $7.60B | $7.60B | +0.0% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.34 | $0.54 | +57.0% | $7.64B | $7.95B | -3.9% |
| — Q2 FY2025 | Jun 25, 2025 | — | -$0.45 | — | $7.24B | — | — |
| ▲ Q1 FY2025 | Jan 30, 2025 | $0.00 | $0.10 | +14663.1% | $7.28B | $7.24B | +0.6% |
| ▲ Q4 FY2024 | Oct 31, 2024 | $0.10 | $0.38 | +266.8% | $7.91B | $7.58B | +4.4% |
| ▲ Q3 FY2024 | Jul 31, 2024 | $0.00 | $0.41 | +33184.6% | $7.52B | $6.79B | +10.8% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.38
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$0.15
EPS Surpr.
+35.2%
Revenue
$6.89B
Q1 FY2026
Jan 29, 2026Beat
EPS Actual
$0.42
EPS Est.
$0.28
EPS Surpr.
+52.4%
Revenue
$7.60B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.54
EPS Est.
$0.34
EPS Surpr.
+57.0%
Revenue
$7.64B
Q2 FY2025
Jun 25, 2025
EPS Actual
-$0.45
EPS Est.
—
EPS Surpr.
—
Revenue
$7.24B
Q1 FY2025
Jan 30, 2025Beat
EPS Actual
$0.10
EPS Est.
$0.00
EPS Surpr.
+14663.1%
Revenue
$7.28B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
$0.38
EPS Est.
$0.10
EPS Surpr.
+266.8%
Revenue
$7.91B
Q3 FY2024
Jul 31, 2024Beat
EPS Actual
$0.41
EPS Est.
$0.00
EPS Surpr.
+33184.6%
Revenue
$7.52B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $95.15 | $98.91 | $103.30 | 1 |
| Q4 FY2027 | $126.20 | $131.18 | $137.00 | 1 |
| Q3 FY2027 | $156.25 | $162.42 | $169.62 | 1 |
| Q2 FY2027 | $55.61 | $57.81 | $60.38 | 1 |
| Q1 FY2027 | $-36.61 | $-35.06 | $-33.72 | 1 |
| Q4 FY2026 | $44.50 | $46.26 | $48.31 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $1083B | $1115B | $1153B | 2 |
| Q4 FY2027 | $1135B | $1169B | $1209B | 3 |
| Q3 FY2027 | $1136B | $1170B | $1210B | 2 |
| Q2 FY2027 | $1109B | $1143B | $1182B | 2 |
| Q1 FY2027 | $1053B | $1084B | $1121B | 3 |
| Q4 FY2026 | $1174B | $1209B | $1250B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +35.2% | $32.68 | $32.68 | +0.00% |
| ▲ Q1 FY2026 | Jan 29, 2026 | +52.4% | $31.12 | $31.12 | +0.00% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +57.0% | $26.80 | $27.35 | +2.05% |
| — Q2 FY2025 | Jun 25, 2025 | — | $28.35 | $28.35 | +0.00% |
| ▲ Q1 FY2025 | Jan 30, 2025 | +14663.1% | $24.94 | $25.99 | +4.21% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +266.8% | $26.69 | $27.00 | +1.16% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +33184.6% | $26.40 | $26.40 | +0.00% |
| ▼ Q2 FY2024 | May 9, 2024 | -276.2% | $25.54 | $26.83 | +5.05% |
Q2 FY2026+0.00%
Report Date
May 13, 2026
EPS Beat/Miss
+35.2%
Price Before
$32.68
Price After
$32.68
Q1 FY2026+0.00%
Report Date
Jan 29, 2026
EPS Beat/Miss
+52.4%
Price Before
$31.12
Price After
$31.12
Q3 FY2025+2.05%
Report Date
Jul 30, 2025
EPS Beat/Miss
+57.0%
Price Before
$26.80
Price After
$27.35
Q2 FY2025+0.00%
Report Date
Jun 25, 2025
EPS Beat/Miss
—
Price Before
$28.35
Price After
$28.35
Q1 FY2025+4.21%
Report Date
Jan 30, 2025
EPS Beat/Miss
+14663.1%
Price Before
$24.94
Price After
$25.99
Q4 FY2024+1.16%
Report Date
Oct 31, 2024
EPS Beat/Miss
+266.8%
Price Before
$26.69
Price After
$27.00
Q3 FY2024+0.00%
Report Date
Jul 31, 2024
EPS Beat/Miss
+33184.6%
Price Before
$26.40
Price After
$26.40
Q2 FY2024+5.05%
Report Date
May 9, 2024
EPS Beat/Miss
-276.2%
Price Before
$25.54
Price After
$26.83
Avg Beat Reaction+1.24%
Avg Miss Reaction+5.05%
Beat Rate6 / 8 quarters
Largest Move+5.05% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TKPHF ends December
Takeda Pharmaceutical Company Limited (TKPHF) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.10 — beating the analyst consensus of $-0.15 by +35.2%. TKPHF has beaten EPS estimates for 6 consecutive quarters. The next TKPHF earnings date is expected around September 1, 2026.
Each quarter, investors track TKPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TKPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TKPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TKPHF earnings · 5 questionsTakeda Pharmaceutical Company Limited's next earnings report is expected around September 1, 2026. TKPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TKPHF historically reports after market close (AMC).
TKPHF earnings datewhen is TKPHF earningsTKPHF next earnings datewhen does TKPHF report earningsTKPHF earnings calendar
▸ Source: FMP · Takeda Pharmaceutical Company Limited SEC filings · US GAAP · Takeda Pharmaceutical Company Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026